eligibility_summary
Eligibility: Adults with MM (IMWG), ≥4 prior regimens incl IMiD, PI, anti‑CD38, received ide‑cel ≤90 days with ≥PR, ECOG ≤2, adequate counts, liver, renal (CrCl ≥30), consent and contraception. Exclusions: prior iberdomide, recent other trials/therapies/surgery/vaccines or strong CYP modifiers, uncontrolled CV/CNS disease, active infection or HIV/HBV/HCV, malignancy within 3 y, active GVHD, amyloidosis/POEMS/plasma cell leukemia, pregnancy, severe IMiD allergy, no thromboprophylaxis, not recovered from chemo.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase I/II trial in relapsed/refractory multiple myeloma post ide-cel tests: Elotuzumab—humanized IgG1 monoclonal antibody targeting SLAMF7 (CS1), activates NK cells and drives ADCC against myeloma cells. Iberdomide (CC-220)—oral cereblon E3 ligase modulator (CELMoD), binds CRBN to degrade IKZF1/3, reducing IRF4/MYC, enhancing T- and NK-cell activation, and exerting anti-myeloma effects. Dexamethasone—oral glucocorticoid, GR agonist causing lympholysis/apoptosis and anti-inflammatory effects. Cells/pathways targeted: SLAMF7 on myeloma and NK cells, CRBN ubiquitin ligase pathway with IKZF1/3 degradation, downstream innate (NK) and adaptive (T-cell) immune activation, glucocorticoid signaling–mediated myeloma apoptosis. Aim: deepen/maintain responses after BCMA CAR-T (ide-cel).